Clinical trials: Lipids
Cushing Syndrome Related to Cortisolic Adenoma
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome
The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the…
- Trial name
- LIPOCUSH (NCT01688349)
- Testing
- analyze the role of glucocorticoid in AT distribution.
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypercholesterolemia
LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe
Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in the liver, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- NCT00677248
- Testing
- Eprotirome and ezetimibe
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karo Bio AB
Fabry Disease, Endothelial Dysfunction
Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study
This study aims to gain a deeper understanding of endothelial dysfunction in patients with Fabry disease through a prospective study of the retinal microvasculature and to identify an objective, non-invasive marker to assess…
- Conditions
- Fabry Disease, Endothelial Dysfunction, Microvasculature
- Trial name
- VASCinFABRY (NCT06758648)
- Testing
- Dynamic retinal vessel analysis (DVA), Biochemistry and immune phenotyping, Questionnaires (Patient reported outcomes)
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Technical University of Munich
CADASIL, CADASIL (Diagnosis)
RAre, But Not aLone: a Large Italian Network to Empower the Impervious diaGNostic Pathway of Rare cerEbrovascular Diseases (ALIGNED)
Cerebrovascular diseases (CVDs) are one leading cause of morbidity and mortality worldwide. Despite intensive investigations, more than 30% of strokes remain of undetermined origin.
- Conditions
- CADASIL, CADASIL (Diagnosis), Moya Moya Disease, Moyamoya
- Trial name
- ALIGNED (NCT06935578)
- Where
- 17 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Hypercholesterolemia
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects
Primary Objective: To assess the safety and tolerability of ascending single SC doses of alirocumab in Chinese healthy subjects. Secondary Objectives: To assess the pharmacokinetic profile of a single SC dose of alirocumab.
- Trial name
- NCT02979015
- Testing
- alirocumab SAR236553 (REGN727)
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Sanofi
Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
This was a placebo-controlled, double-blind, randomized trial in Japanese participants with history of coronary artery disease (CAD) or participants categorized in 'high risk' by JAS 2017 guideline, or Japanese participants with…
- Trial name
- ORION-15 (NCT04666298)
- Testing
- Inclisiran sodium
- Where
- 42 sites in Japan
- Volunteers
- 312 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Dyslipidemias
Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels
This study investigates the causal relationships between antihypertensive and lipid-lowering drugs and inflammatory cytokines using a drug-targeted Mendelian randomization approach.
- Conditions
- Hypertension, Dyslipidemias, Inflammatory Response, Chronic Inflammation
- Trial name
- MRDLT (NCT06622304)
- Where
- China
- Volunteers
- 250,736 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
STEMI, Covid19
Evaluation of the Effect of Long-term Lipid-lowering Therapy in STEMI Patients With Coronavirus Infection COVID-19
It is planned to include 200 patients hospitalized with primary myocardial infarction with and without ST segment elevation (STEMI or NSTEMI) in combination with COVID-19 within the first 15 days from the disease onset.
- Conditions
- STEMI, Covid19, NSTEMI
- Trial name
- CONTRAST-3 (NCT04900155)
- Testing
- Atorvastatin 80mg, Atorvastatin-Ezetimibe
- Where
- Russia
- Volunteers
- 45 people
- Sponsor
- Penza State University
Hypercholesterolemia, Atherosclerosis
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20…
- Conditions
- Hypercholesterolemia, Atherosclerosis, Coronary Artery Disease
- Trial name
- NCT00651378
- Testing
- Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin
- Volunteers
- 87 people
- Sponsor
- Organon and Co
Acute Coronary Syndrome
Lipid Profile in Acute Coronary Syndrome
This study aims to assess the TG/Hdl-c ratio in patients with acute coronary syndrome as a novel marker of atherosclerosis.
- Trial name
- NCT05126043
- Testing
- Triglycerides/high density lipoprotein ratio
- Where
- Egypt
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sohag University
Gaucher Disease
OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease
Gaucher disease is an inherited functional deficiency of glucocerebrosidase. This enzyme breaks down a fatty substance (lipid) called glucocerebroside, which is present in all cells of the body.
- Trial name
- NCT00041535
- Testing
- OGT 918
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Lipid Disorders
Genes Involved in Lipid Disorders
Background: Genes are the instructions our body uses to function. Researchers can look for changes, or variants, in the genes. The goal of this study is to find new gene changes that lead to lipid disorders.
- Trial name
- NCT02311335
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Atherosclerosis, Hypercholesterolemia
The Effect of Fasudil on Vascular Function in Humans
The purpose of the study is to evaluate how the rho kinase inhibitor, fasudil, affects vascular function in patients with atherosclerosis and hyperlipidemia.
- Trial name
- NCT00120718
- Testing
- fasudil
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Hyperglycemia, Hypercholesterolemia
Glucose Metabolism Disorders and Metabolic Syndrome Before and After Primary Hip and Knee Replacement
Osteoarthritis patients undergoing primary hip and knee replacement are followed-up and changes in their glucose metabolism and other metabolic parameters (obesity, cholesterol levels) are examined.
- Conditions
- Hyperglycemia, Hypercholesterolemia, Persistent Postoperative Pain, Hip Replacement
- Trial name
- HyTe-2 (NCT01743313)
- Where
- Finland
- Volunteers
- 155 people
- Sponsor
- Coxa, Hospital for Joint Replacement
Hypercholesteremia, Coronary Artery Disease
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
To evaluate the efficacy of intensive lipid-lowering therapy with Lipitor on the changes of characteristics of yellow coronary plaque in subjects with hypercholesteremia accompanying coronary artery disease
- Trial name
- NCT00408382
- Testing
- atorvastatin, Lipitor
- Where
- 2 sites in Japan
- Volunteers
- 50 people
- Sponsor
- Astellas Pharma Inc
Hyperlipidemia, Dyslipidemia
Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia
The purpose of this study is to demonstrate the superior efficacy of NK-104-CR 8 mg daily compared to Livalo® IR 4 mg daily on fasting serum low-density lipoprotein cholesterol (LDL-C) reduction and to evaluate the comparative…
- Trial name
- NCT02799758
- Testing
- NK-104-CR, Livalo® IR
- Where
- 69 sites in United States
- Sponsor
- Kowa Research Institute, Inc.
Severe Hypertriglyceridemia
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
- Trial name
- NCT05552326
- Testing
- Olezarsen
- Where
- 205 sites in United States, Argentina and 21 more
- Volunteers
- 446 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Vascular Diseases, Hypercholesterolemia
The Effect of Plant Sterols on Vascular Function
The main aim of the study is to investigate, in humans, the effect of plant sterols on vascular function by measuring flow-mediated dilation (FMD).
- Trial name
- NCT01803178
- Testing
- Plant Sterols
- Where
- Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Idiopathic Hypogonadotropic Hypogonadism
Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism
Effects of gonadotrophin replacement therapy Lipid Profile and Oxidative Stress Parameters of Patients with Idiopathic Hypogonadotropic Hypogonadism
- Trial name
- NCT02728440
- Testing
- human chorionic gonadotropin, human menopausal gonadotropin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Dyslipidemias, Hyperlipidemias
A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)
This is a multicenter, Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability, and pharmacokinetics (PK) of PF-07285557 (hereafter, vupanorsen) administered…
- Conditions
- Dyslipidemias, Hyperlipidemias, Hyperlipoproteinemias
- Trial name
- NCT04516291
- Testing
- Vupanorsen
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 286 people
- Sponsor
- Pfizer